Search

Ovid therapeutics Inc

Затворен

СекторЗдравеопазване

2.72 -1.81

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.7

Максимум

2.8

Ключови измерители

By Trading Economics

Приходи

2M

-15M

Продажби

733K

733K

EPS

-0.08

Марж на печалбата

-2,047.476

Служители

23

EBITDA

1.6M

-15M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+158.93% upside

Дивиденти

By Acuity

Следващи печалби

11.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

58M

547M

Предишно отваряне

4.53

Предишно затваряне

2.72

Настроения в новините

By Acuity

50%

50%

135 / 339 Класиране в Healthcare

Ovid therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.09.2026 г., 23:52 ч. UTC

Ovid Therapeutics Inc is higher in after-market trading, reflecting positive momentum since Tuesday's close and positioning above its 20-day moving average.

1.09.2026 г., 20:09 ч. UTC

Ovid Therapeutics Inc is higher today, recovering from an early dip amid broader market dynamics and rising oil prices fueling inflation concerns.

31.08.2026 г., 23:01 ч. UTC

Ovid Therapeutics Inc shares are higher in after-market trading, moving from a low of 0.19% to a high of 4.69%.

28.08.2026 г., 20:07 ч. UTC

Ovid Therapeutics Inc shares are lower today amid rising U.S. Treasury yields and broader market declines. The stock saw notable volatility earlier in the session.

24.08.2026 г., 19:16 ч. UTC

Ovid Therapeutics Inc shares are higher today, recovering from an earlier dip. The stock remains above its 20-day moving average and last month's price.

21.08.2026 г., 19:46 ч. UTC

Ovid Therapeutics Inc is trading higher, maintaining a position near its one-month range. Shares pulled back earlier in the session but are advancing overall.

20.08.2026 г., 23:31 ч. UTC

Ovid Therapeutics Inc shares are higher in after-market trading, reflecting a significant shift in momentum since Thursday's close. No specific news was identified.

19.08.2026 г., 21:21 ч. UTC

Ovid Therapeutics shares declined in after-market trading, finishing near the day's low after peaking earlier in the session. The stock remains above its 20-day moving average.

14.08.2026 г., 19:53 ч. UTC

Social Media

Ovid Therapeutics Inc shares are higher as the company advances its clinical pipeline, with key data releases planned through 2026, attracting positive market sentiment.

13.08.2026 г., 19:16 ч. UTC

Social Media
News

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

12.08.2026 г., 19:46 ч. UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7.08.2026 г., 19:26 ч. UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6.08.2026 г., 22:51 ч. UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5.08.2026 г., 21:03 ч. UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4.08.2026 г., 23:01 ч. UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3.08.2026 г., 19:11 ч. UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31.07.2026 г., 20:02 ч. UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27.07.2026 г., 20:07 ч. UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22.07.2026 г., 18:46 ч. UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20.07.2026 г., 19:36 ч. UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Сравнение с други в отрасъла

Ценова промяна

Ovid therapeutics Inc Прогноза

Ценова цел

By TipRanks

158.93% нагоре

12-месечна прогноза

Среден 7.25 USD  158.93%

Висок 9 USD

Нисък 5 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Ovid therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

6

Купи

0

Задържане

0

Продай

Настроение

By Acuity

135 / 339 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat